For the Inventor, By the Inventor

Enter assignee name

Piramal Enterprises Limited

USPTO Granted Patents = 48

% Expired Patents = 35.4

CIPO Patents = 3

EPO Patents = 20

Trademarks = 4

Forward Citations = 112

Loading Chart...

Loading Chart...

116 inventors (with patents filed for the assignee):

Rajiv Sharma (13 out of 28 patents)

Veena R Agarwal (10 out of 10 patents)

Sanjay Kumar (9 out of 24 patents)

4. Sreesha Srinivasa (7 out of 8 patents)

5. Maggie Rathos (7 out of 11 patents)

6. Kalpana Sanjay Joshi (6 out of 38 patents)

7. Milind Moreshwar Gharpure (6 out of 12 patents)

8. Giridharan Periyasamy (5 out of 5 patents)

9. Somesh Sharma (5 out of 11 patents)

10. Owe Orwar (4 out of 27 patents)

11. Prabha Mishra (4 out of 4 patents)

12. Swati Ajay Piramal (4 out of 7 patents)

13. Muralidhara Padigaru (4 out of 4 patents)

14. Gandhali Ashwin Deshpande (4 out of 4 patents)

15. Vijaykumar Bhagwan Deore (4 out of 4 patents)

Core Competencies:

Pharmaceutical Combination

Cancer Treatment

GPR120 Agonists

SGLT2 Inhibitors

Melanoma

Human Papillomavirus

Synergistic Combinations

Inflammatory Disorders

Hexadepsipeptide Analogues

Kinase Inhibitors

Tricyclic Compounds

Imidazoquinoline Derivatives

48 patents: Sort by Forward Citations

1. 12383530 - Pharmaceutical combination for the treatment of melanoma (2025-08-12),

2. 12383529 - Pharmaceutical combination for the treatment of cancer (2025-08-12),

3. 12076309 - Compounds for the treatment of cancers associated with human papillomavirus (2024-09-03),

4. 11925618 - Pharmaceutical combination for the treatment of cancer (2024-03-12),

5. 11839591 - Pharmaceutical combination for the treatment of melanoma (2023-12-12),

6. 11773077 - Compounds containing carbon-carbon linker as GPR120 agonists (2023-10-03),

7. 11260055 - Oral pharmaceutical composition of lurasidone and preparation thereof (2022-03-01),

8. 11234963 - Pharmaceutical combination for the treatment of cancer (2022-02-01),

9. 11198703 - Process for the preparation of SGLT2 inhibitors and intermediates thereof (2021-12-14),

10. 11160789 - Compounds for the treatment of cancers associated with human papillomavirus (2021-11-02),

11. 11084784 - ROR-gamma modulators and uses thereof (2021-08-10),

12. 11007174 - Pharmaceutical combination for the treatment of melanoma (2021-05-18),

13. 10980776 - Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck (2021-04-20),

14. 10941133 - Compounds containing carbon-carbon linker as GPR120 agonists (2021-03-09),

15. 10688079 - Compounds for the treatment of cancers associated with human papillomavirus (2020-06-23),

Company Overview

Piramal Enterprises Limited, headquartered in Mumbai, India, is a diversified global company with a strong focus on pharmaceuticals and healthcare. The organization specializes in developing innovative therapies, particularly in the fields of cancer treatment and metabolic disorders. Its research encompasses a range of advanced technologies, including pharmaceutical combinations, GPR120 agonists, SGLT2 inhibitors, and ROR-gamma modulators. Piramal is committed to addressing unmet medical needs through its cutting-edge drug development and manufacturing capabilities.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

48 Patents

#12 in Mumbai

#41 in India

#14,550 in the World

Piramal Enterprises Limited

Forward Citations = 112

116 inventors:

Rajiv Sharma (13 out of 28 patents)

Veena R Agarwal (10 out of 10 patents)

Sanjay Kumar (9 out of 24 patents)

4. Sreesha Srinivasa (7 out of 8 patents)

5. Maggie Rathos (7 out of 11 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Piramal Enterprises Limited. Retrieved from https://idiyas.com/company/piramal-enterprises

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…